Medtronic’s diabetes spinoff MiniMed files for IPO (Medtech Dive)

Medtronic’s diabetes business, MiniMed, has formally filed for an IPO, marking a major restructuring move that will create a standalone competitor in the increasingly crowded diabetes technology market—but not without near-term financial and operational headwinds.The filing reveals that MiniMed generated $2.72 billion in revenue in fiscal 2025, while posting a $198 million loss, underscoring the challenge of balancing scale, innovation, and profitability in diabetes devices.